Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
  Phillip Investor Notes

01-06-2020(Mon) 29-05-2020(Fri) 28-05-2020(Thu) 27-05-2020(Wed) 26-05-2020(Tue)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
25 Mar, 2020 (Wednesday)

Ever Sunshine Lifestyle Services Group (1995) offers a comprehensive service portfolio that covers an all-inclusive value chain in property management. The Group operates in three major business lines, namely, (i) property management services, (ii) community value-added services, and (iii) value-added services to non-property owners. For the financial year ended 31 December 2019, the Group recorded revenue of RMB1.877 billion, representing an increase of 74.5% as compared to the same period in 2018. Net profit attributable to shareholders was RMB223.8 million, representing and increase of 122.7%. The Group adhered to rapid expansions on management coverage area as one of its strategic targets, and has achieved speedy growth in contracted GFA and GFA under management through its multi-wheel driven roadmap. (I do not hold the above stock)
Buy-in Price: $7.50, Target Price: $8.50, Cut Loss Price: $6.90

Hengrui Medicine is a pharmaceutical and health enterprise engaged in pharmaceutical innovation and R & D, production and promotion of high-quality drugs. It has more than 20,000 employees worldwide. It is a well-known supplier of anti-tumor drugs, surgical drugs and contrast agents in China, and a national anti-tumor drug The leading unit of the Technology Innovation Industry-University-Research Alliance has a National Targeted Drug Engineering Technology Research Center and a postdoctoral research station. The company has already approved 5 innovative drugs, irenixib, apatinib, 19K, pirlotinib, and carelizumab, and has launched a batch of innovative drugs in clinical development. clinical experiments. In the development of innovative drugs, the company applies for clinical trials of innovative drugs every year. In 2019, the company`s operating income reached 23.289 billion yuan, an increase of 33.70% over the same period last year; the net profit attributable to the owners of the parent company was 5.328 billion yuan, an increase of 31.05% over the same period last year.
Buy-in Price: $83.00, Target Price: $100.00, Cut Loss Price: $73.00

Hisamitsu Pharmaceutical Co., Inc (4530)
Founded in 1847. Manufactures, sells, imports and exports pharmaceuticals and quasi-drugs. ¡§SALONPAS¡¨ has been registered as a trademark in more than 100 countries and regions. Focusing on development of patches based on transdermal drug delivery systems.For 3Q (Mar-Nov) results of FY2020/2 announced on 10/1, net sales decreased by 3.4% to 99.078 billion yen compared to the same period the previous year, and operating income increased by 15.4% to 18.417 billion yen. Sales declined due to the impact of generics in the US ethical drug business and intensified competition in the domestic ethical drug business. However, improvements in the cost of sales ratio and decrease in SG&A expenses had contributed to profit growth.For its full year plan, net sales is expected to increase by 0.1% to 143.5 billion yen compared to the previous year, and operating income to increase by 2.8% to 22.9 billion yen. On 12/3, the Nikkei Keizai Shimbun reported that apparently full-year sales will decrease by 3%, and operating income will increase by 5%. ¡§Haruropi Tape¡¨, a transdermal therapeutic agent for Parkinson's disease, released in Japan in 2019/12 is contributing to operating income. Demand is expected to increase as tremors in limbs due to ageing become a social problem as the population ages.Target Price : 5,228 yenBuy Price : 4,350 yenCut-Loss : 3,751 yen

Jonjee Hi-Tech (600872.CH) - Production Capacity Increase and Channel Expanded Advanced Orderly

Investment Summary

In Nearly 20% Increase in Earnings Last Year

Jonjee Hi-Tech reported revenues of RMB4675 million in 2019, an increase of 12.20% yoy; a net profit attributable to the shareholders of the listed company of RMB718 million, an increase of 18.19% yoy, and an EPS of RMB0.9 compared with an EPS of RMB0.76 last year. The result was basically in line with our expectations at the beginning of last year (3.2% lower than expectation). The cash dividend per share was RMB0.28, and the dividend payout rate remained 31%.

Condiment Business Result Remained Fast Growth with A Nearly 30% Increase In Profit, and Minor Categories Made Achievements

The result of company's condiment sector maintained a fast growth, the annual revenue of Meiweixian in 2019 was RMB4468 million, up by 15.98% yoy, an 6% increase in growth rate compared with last year; the company reported a net profit of RMB796 million, up 27.6% yoy. The accelerated growth of condiment results was mainly attributed to: (1) the Lunar New Year arrived earlier this year, and the delivery and expense settlement were advanced to the end of this year. (2) The overall cost of raw materials stayed low and the Company implemented a centralized management and control model of purchasing in 2019, bringing a RMB62 million reduction in procurement costs throughout the year (excluding grease). (3) The Company increased its investment in marketing promotion in immature regions, and the expense and revenue elasticity increased.

By products, soy sauce reported a revenue of RMB2.88 billion, up 11.23% yoy; chicken essence and chicken extract reported a revenue of RMB527 million, up 18.99% yoy; edible oil reported a revenue of RMB447 million, up 39% yoy; other condiments reported a revenue RMB580 million, a year-on-year increase of 26%.

By channels, household consumption reported a revenue of RMB3744 million, a 10.8% increase; catering consumption recorded a revenue of RMB1496 million, a 23.5% increase, and the proportion of catering channels increased by about 2 ppts to 28%. Catering exploitation yielded remarkable results.

By regions, the condiment revenue in the eastern, southern, mid-western, and northern regions increased by 12%, 12%, 25%, and 20%, respectively. The development of new regions in the mid-western and northern regions was enhanced. The Company newly developed 21 prefecture-level cities, which means 281 of the 337 prefecture-level cities nationwide have been developed, with a development rate of 83% and a 38% development rate at district and county level. At the end of 2019, the number of dealers was 1,051, and 187 were newly opened. It is expected that number of dealers would reach 1,300 by the end of 2020, up 24% yoy.

Gross Margin Increased, and Operational Efficiency Continued to Improve

Benefiting from the reduction of VAT rate, the slight decrease in the price of raw materials such as packaging materials and additives, and the decrease in manufacturing costs brought by the increase in production efficiency, the gross margin of Meijixian increased by 0.36 ppts to 39.56%, and the net profit margin increased by 1.49 ppts to 16.32%. The gross margin of soy sauce, chicken essence and chicken extract, edible oil, and other products was 45.82% / 39.46% / 13.06% / 28.32%, respectively, with changes of + 1.69 / -1.27 / -5.36 / + 2.86 ppts yoy. The scale effect of rising production and falling price of packaging materials are the main reasons for the increase in gross margin of soy sauce, while the price increase in raw materials is the reason for the decline in the gross margin of chicken extract and edible oil.

The period cost rate totalled 18.59%, a decrease of 0.9 ppts compared with the same period of last year, among which the sales expense decreased significantly, the sales expense rate and the administration expense rate down 0.91 ppts and 0.25ppts, respectively, and the operational efficiency continued to improve.

During the period, the Company's cash flow from operating activities recorded a net inflow of RMB1059 million, a significant increase of 46.3% yoy, which mainly attributed to the increase in the revenue of Meiweixian and the increase in the collection of loans and the revenue of Jonway housing sales, and the cash flow was greatly improved.%.

Production Capacity Increase and Channel Expanded Advanced Orderly

The Company mentioned the 5-Year Goal of Double Hundred, which was to reach 1 million tons of output and RMB10 billion in revenue by 2023. In order to achieve this objective, the Company has not only steadily promoted the second-phase expansion project of the Yangxi Plant, but also planned to invest RMB1275 million to upgrade and expand the Zhongshan Plant to increase the production capacity from the current 314,300 tons to 584,200 tons, of which the soy sauce production capacity would increase from 230,000 tons to 480,000 tons, and newly-added cooking wine production capacity would be 20,000 tons. The plan will be activated in March 2020 and completed by the end of 2022. It is estimated that the project will bring in a revenue increase of RMB1575 million and net profit of RMB355 million. On the other hand, channel sinking and employee incentives will be enhanced. The development rate of prefecture-level cities will be increased to 87.83%, and the development rate at district and county level will reach 46.23%. We-Media and online advertising will continue to be strengthened.

Investment Thesis

After Baoneng taking over the company, the improvement of the incentive mechanism and management efficiency will lay a foundation for the Company's long-term development. The narrowing of the gap with the first-tier companies is also expected to open up space for the company's growth.

We expected diluted EPS of the Company to RMB 1.05/1.31 of 2020/2021. And we accordingly gave the target price to RMB 45, respectively 43/34x P/E for 2020/2021. "Accumulate" rating maintained. (Closing price as at 23 March)


Price war among peers

Raw material price increase

New business risk


Click Here for PDF format...

Recommendation on 25-3-2020
Price on Recommendation Date$ 41.500
Suggested purchase priceN/A
Target Price$ 45.000
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%

A-H spread
Stock Code H share
A share
H share

Oversea Research Reports

Investment Service Centre

Enquiry : 2277 6666 OR
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2020 Phillip Securities (HK) Ltd. All Rights Reserved.

Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]